Experienced in Childhood Iron Deficiency Anemia

Dr. Sherman R. Baker

Internal Medicine
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Childhood Iron Deficiency Anemia
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sherman Baker is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Baker is rated as an Experienced provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Baker is currently accepting new patients.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1250 E Marshall St, Internal Medicine, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
View 5 Less Clinical Trials

15 Total Publications

Standardization of a silver stain to reveal mesoscale myelin in histological preparations of the mammalian brain.
Standardization of a silver stain to reveal mesoscale myelin in histological preparations of the mammalian brain.
Journal: Journal of neuroscience methods
Published: January 18, 2024
Similar Doctors
Advanced in Childhood Iron Deficiency Anemia
Dr. Peter J. Zullo
Internal Medicine
Advanced in Childhood Iron Deficiency Anemia
Dr. Peter J. Zullo
Internal Medicine

Riverside Physician Services Inc

7547 Medical Dr, Suite 2200, 
Gloucester, VA 
 (49.5 miles away)
804-693-2720
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Zullo is a primary care provider, practicing in Internal Medicine in Gloucester, Virginia. Dr. Zullo is rated as an Advanced provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Cerebellar Degeneration, Sitosterolemia, and Corticobasal Degeneration. Dr. Zullo is currently accepting new patients.

Advanced in Childhood Iron Deficiency Anemia
Dr. Andrea J. Alejo
Internal Medicine
Advanced in Childhood Iron Deficiency Anemia
Dr. Andrea J. Alejo
Internal Medicine

Riverside Physician Services Inc

7547 Medical Dr, Suite 2200, 
Gloucester, VA 
 (49.5 miles away)
804-693-2720
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrea Alejo is a primary care provider, practicing in Internal Medicine in Gloucester, Virginia. Dr. Alejo is rated as an Advanced provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. Her top areas of expertise are Childhood Iron Deficiency Anemia, Chronic Pain, Nephrosclerosis, and Renovascular Hypertension. Dr. Alejo is currently accepting new patients.

Advanced in Childhood Iron Deficiency Anemia
Dr. Rocco J. Basciano
Geriatrics | Internal Medicine
Advanced in Childhood Iron Deficiency Anemia
Dr. Rocco J. Basciano
Geriatrics | Internal Medicine

Riverside Physician Services Inc

856 J Clyde Morris Blvd, Suite C, 
Newport News, VA 
 (62.1 miles away)
757-316-5725
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rocco Basciano is a primary care provider, practicing in Geriatrics and Internal Medicine in Newport News, Virginia. Dr. Basciano has been practicing medicine for over 47 years and is rated as an Advanced provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Spinal and Bulbar Muscular Atrophy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Spinal Muscular Atrophy (SMA). Dr. Basciano is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baker's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile